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COMMENTARY
Abstract: There are major differences between the current knowledge of the treatment of
cardiac conditions derived from evidence-based medicine and the widespread application of
this knowledge. This is particularly true in the treatment of hypertension. Hypertension is the
most common chronic cardiovascular condition, affecting more than 50 million Americans
and approximately 1 billion individuals worldwide. However, many hypertensive patients are
not receiving treatment, and of those that are, many are not adequately controlled. There is
evidence that there are methods to improve blood pressure control and improve compliance
with expert recommendations for the treatment of hypertension. These methods range from
local initiatives such as academic detailing to national performance measures as have been
developed by the US Department of Veterans Affairs. A challenge for the future will be to
identify and broadly apply these and other programs to improve the quality and efficiency of
hypertensive treatment.
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Over the past 60 years, the treatment of cardiovascular diseases has made revolutionary
progress. The development of cardiopulmonary bypass, angioplasty, and the use of
lasers are just a few of the technological innovations that are available for the treatment
of patients suffering from cardiac disease. Equally impressive are findings from well
controlled and executed clinical trials that have established medical treatments for
many cardiac conditions. Yet, many of these treatments are underutilized. This has
been particularly true for hypertension in many different clinical settings (Goldstein
et al 1994; Berlowitz et al 1998; Hyman and Pavlik 2001; Jackson et al 2002).
Blood pressure control
Hypertension is the most common chronic cardiovascular condition, affecting more
than 50 million Americans and approximately 1 billion individuals worldwide (NHLBI
2003). The benefits of lowering blood pressure in hypertensive individuals on the
morbidity and mortality associated with cardiovascular and renal disease has been
established in many randomized controlled trials (SHEP Cooperative Research Group
1991; The ALLHAT 2002; Blood Pressure Lowering Treatment Trialists’
Collaboration 2003), including the seminal Department of Veterans Affairs (VA)
study published in 1970 (Veterans Administration Cooperative Study Group on
Antihypertensive Agents 1970).
However, data from the National Health and Nutrition Survey (NHANES) III
indicate that only 46% of men and 65% of women with blood pressure ≥ 140/90 mmHg
are currently receiving antihypertensive treatment in the US (Burt et al 1995).
 Of
those under treatment, only 50% of men and 58% of women are adequately controlled.
This includes patients 65 years of age and older as well as younger patients (Glynn et al
1995). Strategies to improve blood pressure control as well as decisions concerning
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the best pharmacological treatment for these patients will
have major morbidity and mortality consequences, as well
as important implications for the cost of medical care.
Currently, US national hypertensive treatment is at odds
with published guidelines from national bodies. In older
studies of different populations and different time periods,
there has been an increased use of calcium antagonists and
ACE inhibitors, with a parallel decline in the use of thiazide
diuretics and β-blockers (Siegel and Lopez 1997). This
change in antihypertensive drug use occurred despite
recommendations from The Fifth and Sixth Reports of the
Joint National Committee on Detection, Evaluation, and
Treatment of High Blood Pressure (JNC V and VI) that
hydrochlorothiazide and β-blockers be used as first-choice
agents if there are no other specific indications. This is
because they have been shown in long-term controlled
clinical trials to reduce cardiovascular morbidity and
mortality as well as or better than other classes of
antihypertensives, and they are far less expensive (JNC 1993,
1997).
The US is not alone in this problem. Studies performed
in Canada and the United Kingdom of patients newly treated
for hypertension show variability in the choice of initial
medication. ACE inhibitors and calcium antagonists were
more commonly prescribed in the Canadian province of
Saskatchewan (Bourgalt et al 2001), whereas diuretics or
β-blockers accounted for 54% of new prescriptions in Britain
(Walley et al 2003). In the US, data from the National
Ambulatory Care Medical Surveys of office-based
physicians has been used to evaluate antihypertensive
treatment from 1980 to 1995 (Nelson and Knapp 2000).
Trends in this study included a decrease in diuretic use and
an increase in calcium antagonist and ACE inhibitor use.
More recently, a study of Maine Medicaid databases for
1994, 1997, and 1999 reported high use of ACE inhibitors
and calcium antagonists (Clause and Hamilton 2002).
Barriers to blood pressure control
Why only a small proportion of hypertensives achieve
recommended blood pressure reduction targets is likely to
be multifactorial including patient belief systems dismissing
hypertension as a significant medical problem, lack of
consistent medical follow-up, provider failure to adjust drug
regimens to achieve control, medication side effects and
Table 1 Impediments to and potential strategies for effective blood pressure control
Impediments Possible interventions
Patient-based
Attitudes about hypertension Education at the community and individual level concerning consequences of hypertension
Medication side effects Use of medications with fewer side effects
Education of and treatment for sexual side effects
Medication cost Use of diuretics and other generically available medication
Medication adherence Less frequent dosing of medications
Promotion of pillboxes
Combination medications
Methods to increase ease of medication renewal (ie, telephone or computer-linked)





Publication of clinical trials
Access Use of physician extenders
Group visits
Work site care
Expansion of health coverage
Awareness Computer based reminders
Motivation Incentives for health providers and managers
Societal-based
Awareness Public education campaigns
Community-screening programs
Work-based programs
Access to care Expansion of health coverage (private and government financed)Vascular Health and Risk Management 2005:1(1) 11
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dosing, lack of economic resources to access healthcare or
purchase medications, and lack of adherence with
medications (Table 1) (Egan and Basile 2003; Nelson et al
2003). Hypertension is also frequently complicated by
comorbid conditions which makes its treatment more
complicated (Meier et al 1999).
Poor medication adherence is an important problem in
the management of hypertension. Patients with hypertension
are often asymptomatic. The disease then lacks a tangible
reinforcement factor to foster medication adherence in
contrast with what may be seen in other chronic conditions
such as diabetes where symptoms of hyperglycemia remind
the patient about the need to take medications.
The decision to manage the hypertensive patient with
medications often results in lifelong therapy. Medications
bring along symptoms from side effects enforcing the belief
that the cure is worse than the disease. Failure to refill
medications as expected occurred in 33% of refill
opportunities in one study (Bailey et al 1996). Medication
refill patterns have been correlated to blood pressure control
and, as would be expected, failure to refill on time
corresponds to patients not taking the medication on a
regular basis thus losing blood pressure control (Steiner et
al 1988).
Barriers to effective prescribing
practices
The prescribing of medication is a complex phenomenon.
It is assumed that the skills needed to prescribe medication
are acquired during medical training and are sustained
during clinical practice by effective continuing medical
education (CME). It is hypothesized that scientifically based
prescribing patterns are based, at least in part, on the
publication, interpretation, and application of results from
scientifically sound clinical trials, attendance at CME
meetings, or recommendations from expert medical
organizations or panels that are then applied to the care of
individual patients. There is much evidence that these
assumptions are incorrect for the treatment of many
cardiovascular conditions including hypertension. There are
medical treatments of proven morbidity and mortality
benefit for congestive heart failure, atrial fibrillation,
dyslipidemias, hypertension, and for patients after
myocardial infarction. Current evidence including that cited
above indicates that these treatments are underutilized
resulting in premature morbidity and mortality (Siegel 2000;
Amsterdam et al 2002).
Why might this be the case? It is unlikely that differences
of opinion based on different interpretations of scientific
evidence are the primary basis for widespread differences
in the use of medications. The use of calcium antagonists
for the various manifestations of cardiovascular disease is
not only of unproven mortality benefit (Conti 1996), but
findings from retrospective noninterventional studies raise
concerns that short-acting calcium antagonists are associated
with serious adverse effects in hypertensive patients and
thus should be avoided except in rare circumstances (Buring
et al 1995; Psaty et al 1995). Despite this controversy played
out in medical journals and at national meetings, most
practitioners from around the world, including the US, were
unaware of the calcium antagonist debate, despite
widespread media coverage (Hobbs 1997).
In the case of hypertension, expert recommendations
may have had little impact on antihypertensive prescribing
patterns because of the lack of successful dissemination of
these recommendations, the effectiveness of pharmaceutical
promotion practices, or the attractiveness of using new
therapies so that practitioners are considered up-to-date. Of
these, the role of pharmaceutical promotion practices,
including face-to-face sales activities and pharmaceutical
advertisements, has probably had the greatest impact
(Soumerai 1988; Soumerai et al 1989; Wilkes et al 1992).
Misinformation about the role of drugs may stem from
inaccurate drug advertisements and inaccurate statements
made by pharmaceutical representatives (Wilkes et al 1992;
Ziegler et al 1995). These intense promotional efforts of
pharmaceutical companies to influence prescribing patterns
for financial reasons may result in the prescribing of
medications that are inferior or at best equivalent to other
treatments. The end result is that medication use often differs
from well developed clinical practice guidelines that are
usually based on the best available evidence from clinical
trials.
Strategies to improve medication
use
What can be done to improve patterns of medication use
(Table 1)? One approach would be to improve how
guidelines are formatted, organized, and disseminated
(Lenfant 1997), although this is unlikely to have a major
impact. A review of 99 studies of methods to change
physicians’ practice concluded that educational materials
alone and formal CME conferences or activities, without
enabling or practice-reinforcing strategies, had relativelyVascular Health and Risk Management 2005:1(1) 12
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little impact (Davis et al 1995). The most commonly
effective single-method interventions were outreach visits,
including academic detailing, patient reminders and
educational materials, and physician reminders.
Academic detailing, originally developed in the early
1980s, was termed counter-detailing to indicate the
promotion of drug use and to counter the pharmaceutical
industry’s overpromotion of other drugs (Soumerai 1988;
Soumerai et al 1989). It uses the pharmaceutical industry
method of drug detailing to promote an institution’s desired
use of drugs or other elements of patient care, and involves
face-to-face meetings of providers with typically a
pharmacist or another healthcare provider. At the meeting,
often of just a few minutes duration, the detailer explains
the specific area of promotion and leaves written materials
as reference. While not extensively studied, research
suggests that academic detailing is a useful way to improve
prescribing practices and to successfully implement practice
guidelines (Davis et al 1995; Barreuther 1997).
In a recent VA study, academic detailers met with
providers to discuss their past prescribing of anti-
hypertensive medications and to suggest changes that would
bring their practice more into compliance with JNC VI
guidelines (Siegel et al 2003). Over the initial six-month
period following the first meeting, thiazide diuretic use
increased by 20% and calcium channel blocker use
decreased by 11%.
Different approaches to the prescribing of medication
might improve patient adherence. Changes in dosing
schedules have been tried. In one study, enalapril once daily
compared with twice daily resulted in no differences in
treatment outcomes (Girvin et al 1999). Combination
therapy might simplify dosing schedules but usually at the
expense of increased costs.
Other approaches may result in improvement of care.
Change in practice-wide systems may improve medication
prescribing as well as other healthcare practices (Pearson
et al 1996). These include disease state or case management,
the use of information systems to prompt treatment of
appropriate patients, and other quality improvement
strategies. Appropriate public education campaigns may also
be useful as well as other interventions aimed at the patient.
This appears particularly important given the large number
of hypertensives that remain untreated (Burt et al 1995).
All of these approaches require further study to determine
which are the most effective.
Other efforts to improve
hypertensive treatment in the US
Department of Veterans Affairs
Approximately 40% of VA patients have hypertension due,
in part, to its older population (Meier et al 1999).
Consequently, medications used to control hypertension are
used extensively in VA. To address the large hypertensive
disease burden on the healthcare system, VA has developed
and promoted hypertension management guidelines that
closely resemble JNC VI (Department of Veterans Affairs
Medical Advisory Panel 1996). This has been part of a
program to improve clinical outcomes via quality
improvement initiatives. National performance measures
starting in the late 1990s tracked the proportion of patients
achieving target blood pressure and set increasing targets
for the proportion of patients that should be at their goal.
Perhaps partly due to these performance measures, data from
a study of quality indicators demonstrated that VA out
performs private-sector US healthcare systems (Jha et al
2003). VA antihypertensive medication utilization trends for
1997–1999 suggested a downward trend in calcium
antagonist use and an increase in β-blocker and thiazide
diuretic use (Siegel et al 1998, 2001).
This continued shift from calcium antagonists to
β-blockers and diuretics plus the large use of ACE inhibitors
indicate greater adherence to treatment guidelines. Emphasis
on evidence-based medicine together with the publication
of clinical trials suggesting a lack of benefit for calcium
antagonist use and safety concerns such as gastrointestinal
bleeding or cancer may have had an impact on medical
practice regarding this antihypertensive drug class (Psaty
et al 1995; Pahor, Guralnik, Furberg, et al 1996; Pahor,
Guralnik, Salive, et al 1996). However, in accord with recent
data on VA’s quality, we feel the strongest agent for change
in hypertension management and for the shift in medication
use patterns are VA’s performance measures (Jha et al 2003).
These measures grade a VA, develop accountability, and
may have institutional financial incentives associated with
meeting targets. This managerial approach to improving care
has the net effect of engaging clinical managers, who sign
performance contracts, and practitioners toward achieving
specific measurable goals. This approach has resulted in
improved hypertension control while producing savings in
drug expenditures. The use of performance measurement
as a way to improve quality in VA has, at least in part,
increased the number of VA hypertensive patients with bloodVascular Health and Risk Management 2005:1(1) 13
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pressures of less than 140/90 mmHg from a baseline of 25%
in 1994–1995 to 46% in 2000 (Jha et al 2003). Although
not in place long enough to be evaluated by Jha et al (2003),
the use of clinical reminders generated by the VA electronic
medical record may have additional benefits for blood
pressure control.
Conclusions
The need for physicians to remain up-to-date regarding
improvements in medication use, procedures, and
diagnostics is obviously important. Yet, there is a serious
gap between current knowledge of the treatment of cardiac
conditions derived from evidence-based medicine and the
widespread application of this knowledge. Evidence from
VA suggests that there are methods to improve the
prescribing of medication, including academic detailing and
the promotion of system-wide performance measures. It is
not known if changes in antihypertensive medication use in
VA are also occurring in non-VA settings. However, it
appears that thiazide diuretics continue to be underutilized
in hypertensive treatment. The recent publication of results
from The Antihypertensive and Lipid-Lowering Treatment
to Prevent Heart Attack Trial (ALLHAT), which noted that
thiazide diuretics were superior to calcium antagonists and
ACE inhibitors in several areas, underscores this concern
(The ALLHAT 2002). ALLHAT study findings, now
incorporated into the JNC-7 guidelines, focus the therapy
of uncomplicated hypertension on thiazide diuretics
(Chobanian et al 2003). Hopefully, lessons learned from
the successful reengineering of the VA healthcare system
will lead to a more widespread adherence to these and similar
guidelines.
The views expressed in the article do not necessarily
represent the views of the Department of Veterans Affairs
or of the United States Government.
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